rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Richard Peters

Director

Company insider

Files Form 4 as: Director, Aprea Therapeutics; President and CEO, Kineta, Inc./de; President and CEO, Merrimack Pharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
46
Buys
0
Sells
4
Bought
$0
Sold
$59K
Companies
3
Companies where not an officer
1
First trade
6 Jun 2017
Last trade
16 Jun 2026
Last filed
17 Jun 2026

Companies traded

Where they are an officer
Kineta, Inc./deDirector, Officer · last 30 Jun 20250 buys · 4 sells
Merrimack PharmaceuticalsDirector, Officer · last 8 May 20190 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
APRE Aprea TherapeuticsDirector · Biotechnology · last 16 Jun 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
16 Jun 2026filed 17 Jun 2026APRE Aprea TherapeuticsBiotechnologySEC FORM 4 Code A—3,135 at $0.00filing
16 Jun 2026filed 17 Jun 2026APRE Aprea Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—12,555 at $0.00filing
16 Jun 2026filed 17 Jun 2026APRE Aprea Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—12,555 at $0.00filing
16 Jun 2026filed 17 Jun 2026APRE Aprea TherapeuticsBiotechnologySEC FORM 4 Code A—3,135 at $0.00filing
31 Mar 2026filed 1 Apr 2026APRE Aprea Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code P$100K123,915 at $0.807filing
31 Mar 2026filed 1 Apr 2026APRE Aprea Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code P—123,915filing
31 Mar 2026filed 1 Apr 2026APRE Aprea Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code P$100K123,915 at $0.81filing
31 Mar 2026filed 1 Apr 2026APRE Aprea Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code P—123,915filing
30 Jun 2025filed 2 Jul 2025Kineta, Inc./deoption or derivativeSEC FORM 4 Code D—12,500 at $0.00filing
30 Jun 2025filed 2 Jul 2025Kineta, Inc./deoption or derivativeSEC FORM 4 Code D—20,000 at $0.00filing
30 Jun 2025filed 2 Jul 2025Kineta, Inc./deSEC FORM 4 Code D—101,891filing
25 Jun 2025filed 25 Jun 2025Kineta, Inc./deSEC FORM 4 Code A—6,000 at $0.00filing
23 Jun 2025filed 25 Jun 2025Kineta, Inc./deoption or derivativeSEC FORM 4 Code M—12,500 at $0.00filing
23 Jun 2025filed 25 Jun 2025Kineta, Inc./deSEC FORM 4 Code M$7,62512,500 at $0.61filing
23 Jun 2025filed 25 Jun 2025Kineta, Inc./deSEC FORM 4 Code F$1,2244,706 at $0.26filing
5 Jun 2025filed 9 Jun 2025APRE Aprea Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—4,185 at $0.00filing
5 Jun 2025filed 9 Jun 2025APRE Aprea TherapeuticsBiotechnologySEC FORM 4 Code A—1,045 at $0.00filing
4 Sep 2024filed 5 Sep 2024Kineta, Inc./deoption or derivativeSEC FORM 4 Code A—12,500 at $0.00filing
20 Jun 2024filed 21 Jun 2024APRE Aprea Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—4,185 at $0.00filing
20 Jun 2024filed 21 Jun 2024APRE Aprea TherapeuticsBiotechnologySEC FORM 4 Code A—1,045 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed4

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.